Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 3.5Cr |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.59% | -6.25% | +64.99% | +99.09% | 7.06TCr | |
| -1.34% | +1.13% | +47.33% | +90.79% | 6.61TCr | |
| -8.36% | -12.06% | +0.57% | -15.05% | 2.8TCr | |
| +0.14% | -5.90% | -12.32% | +447.39% | 2.65TCr | |
| +0.30% | +2.03% | +59.48% | +14.21% | 2.64TCr | |
| -0.96% | +12.36% | +280.38% | +439.54% | 2.04TCr | |
| -0.51% | +0.70% | +35.85% | -16.21% | 2.02TCr | |
| -1.91% | -3.47% | +11.03% | +508.52% | 1.6TCr | |
| -1.44% | +0.91% | +43.98% | +146.03% | 1.37TCr | |
| Average | -1.68% | +1.49% | +59.03% | +190.48% | 3.2TCr | |
| Weighted average by Cap. | -1.70% | +1.52% | +56.28% | +151.39% |
